Form 13-F position report

IOVANCE BIOTHERAPEUTICS INC CO

Reported by Soleus Capital Management L P

Company profile Manager portfolio Source filing
IOVA CUSIP 462260100 Manager CIK 0001802630
Latest reported change

Reported 7,785,000 shares, up 1,225,000 (18.7%) from the prior quarter.

Reported value -46.6%; share count 18.7% vs. the prior quarter.

Added
% of reported 13F value 1.87% This manager · Q1 2025
Shares 7,785,000 Quarter-end amount reported
Reported value $25,924,050 Fair value at quarter end
Consecutive quarters held 12 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Reduced 150,000 -850,000 (-85.0%) 0.02% $624,000 2026-08-11
Q1 2026 New 1,000,000 +1,000,000 (0.0%) 0.14% $3,510,000 2026-05-14
Q4 2025 Reduced 0 -976,707 (-100.0%) 0 $0 2026-02-12
Q3 2025 Reduced 976,707 -2,285,000 (-70.1%) 0.11% $2,119,454 2025-11-14
Q2 2025 Reduced 3,261,707 -4,523,293 (-58.1%) 0.37% $5,610,136 2025-08-15
Q1 2025 Added 7,785,000 +1,225,000 (18.7%) 1.87% $25,924,050 2025-05-15
Q4 2024 Reduced 6,560,000 -1,968,500 (-23.1%) 3.05% $48,544,000 2025-02-14
Q3 2024 Added 8,528,500 +980,500 (13.0%) 6.2% $80,082,615 2024-11-14
Q2 2024 Added 7,548,000 +4,043,000 (115.3%) 5.34% $60,534,960 2024-08-14
Q1 2024 Added 3,505,000 +2,950,000 (531.5%) 3.86% $51,944,100 2024-05-15
Q4 2023 Reduced 555,000 -684,777 (-55.2%) 0.5% $4,512,150 2024-02-14
Q3 2023 Unchanged 1,239,777 0 (0.0%) 0.52% $5,640,985 2023-11-14
Q2 2023 Reduced 1,239,777 -210,000 (-14.5%) 0.97% $8,728,030 2023-08-14
Q1 2023 New 1,449,777 +1,449,777 (0.0%) 0.92% $8,858,137 2023-05-15
Q4 2022 Reduced 0 -1,025,200 (-100.0%) 0 $0 2023-02-14
Q3 2022 Added 1,025,200 +305,600 (42.5%) 1.33% $9,821,000 2022-11-14
Q2 2022 New 719,600 +719,600 (0.0%) 1.24% $7,944,000 2022-08-15
Institutional context

Who else reported the position

358 managers reported IOVANCE BIOTHERAPEUTICS INC CO for Q1 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 27,777,778 +243,438 < 0.01% $92,500,000 32 qtrs
MHR FUND MANAGEMENT LLC Unchanged 24,417,103 0 9.77% $81,308,953 10 qtrs
BlackRock Inc Added 24,314,578 +838,543 < 0.01% $80,967,543 3 qtrs
PERCEPTIVE ADVISORS LLC Reduced 12,711,788 -9,400,478 1.5% $42,330,254 32 qtrs
STATE STREET CORPORATION Reduced 11,041,322 -1,207,960 < 0.01% $36,767,602 32 qtrs
Long Focus Capital Management LLC Added 9,250,055 +4,118,055 1.03% $30,802,683 14 qtrs
Hood River Capital Management LLC Added 9,216,040 +224,467 0.52% $30,689,413 8 qtrs
Soleus Capital Management L P This report Added 7,785,000 +1,225,000 1.87% $25,924,050 12 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 5,968,298 +96,878 < 0.01% $19,878,539 32 qtrs
UBS ASSET MANAGEMENT AMERICAS INC Added 5,777,344 +3,869,617 < 0.01% $19,238,556 32 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
7,785,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.